Table 2 LAT1 expression in 138 patients with Non-Hodgkin’s lymphoma (WHO classification).
From: Expression of L-type amino acid transporter 1 is a poor prognostic factor for Non-Hodgkin’s lymphoma
Lymphoma type | No. of patients | LAT1 expression level (%) Median (SD) | Range (%) |
|---|---|---|---|
All types | 138 | 42.4 (± 29.5) | 1.9–99.2 |
Diffuse large B-cell lymphoma (DLBCL) | 30 (21.7%) | 80.1 (± 19.9) | 4.2–98.2 |
GCB type | 17 | 69.6 (± 23.1) | 4.2–93.2 |
Non- GCB type | 13 | 82.2 (± 11.6) | 58.2–98.2 |
Follicular lymphomas (FL) | 69 (50%) | 24.9 (± 21.2) | 3.9–99.2 |
Grade 1–2 | 41 | 22.6 (± 13.8) | 3.9–76.6 |
Grade 2 | 6 | 26.9 (± 11.1) | 10.8–40.6 |
Grade 3A | 19 | 39.9 (± 23.8) | 10.5–99.2 |
Grade 3B | 3 | 81.2 (± 9.9) | 73–92.3 |
Marginal zone B-cell lymphoma (MZL) | 5 (3.6%) | 17.4 (± 16.2) | 7.7–49 |
Burkitt lymphoma (BL) | 3 (2.2%) | 95.6 (± 0.5) | 95.2–96.2 |
Mantle cell lymphoma (MCL) | 6 (4.3%) | 3.9 (± 1.6) | 1.9–6.5 |
Small lymphocytic lymphoma (SLL) | 2 (1.4%) | 3.8 (± 1.5) | 2.7–4.8 |
Peripheral T-cell lymphoma (PTCL) | 7 (5.1%) | 44.7 (± 28.4) | 16.2–96.8 |
Angioimmunoblastic T-cell lymphoma (AITL) | 6 (4.3%) | 45.6 (± 8.4) | 34.4–58.4 |
Anaplastic large cell lymphoma (ALCL) | 5 (3.6%) | 73.4 (± 30.1) | 24.8–95.7 |
Extranodal Natural Killer/T cell lymphoma nasal type (ENKTCL nasal) | 5 (3.6%) | 39.4 (± 24.5) | 11.8–64.5 |
